Palatin Technologies, Inc. (PTN) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights significant progress in product development, with promising next-generation compounds and a strong focus on differentiation, which is positively viewed by analysts. The financial performance shows reduced losses and a strong cash position, supporting future growth. The Q&A reveals confidence in the pipeline's potential and strategic prioritization. Despite some uncertainties in timelines and preclinical outcomes, the overall sentiment is positive, suggesting a likely stock price increase of 2% to 8% over the next two weeks.
Key Financial Performance
Revenue $3.9 million in collaboration and license revenue for the third quarter, compared to no revenue in the prior year period. The increase was primarily related to the revenue recognition of the upfront consideration under the Altanispac agreement.
Operating Expenses $5.5 million for the quarter, compared to $4.8 million in the prior year period. The increase was primarily attributable to higher compensation costs and professional fees.
Net Cash Used in Operations $4.4 million for the quarter, compared to $5.4 million in the prior year period. The reduction was primarily driven by collaboration and license revenue recognized during the quarter.
Net Loss $1.4 million or $0.37 per basic and diluted common share for the third quarter of fiscal 2026, compared to a net loss of $4.8 million or $9.13 per basic and diluted common share for the prior year period. The improvement was primarily related to collaboration and license revenue recognized during the quarter.
Cash and Cash Equivalents $10.2 million as of March 31, 2026, in addition to approximately $2.2 million of other receivables expected to be collected during the quarter ending June 30, 2026.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Melanocortin-4 receptor agonist peptide program: The program is designed for sustained efficacy with high selectivity for the melanocortin-4 receptor and a once-weekly delivery. It is on track for an initial new drug application submission in Q4 2026.
Oral small molecule program: Advancing next-generation oral melanocortin-4 receptor selective agonist candidates with improved selectivity and potency. IND submission is planned for the first half of 2027.
Partnership with Boehringer Ingelheim: Focused on retinal diseases, providing nondilutive capital, milestone opportunities, and potential long-term royalty participation. Received upfront and milestone payments totaling approximately $8.8 million in 2025.
Sublicensing of PL-9643: Sublicensed for dry eye disease to Altanispac Labs in January 2026, receiving $3.8 million in upfront consideration with potential for future payments and royalties.
Financial performance: Recognized $3.9 million in collaboration and license revenue in Q3 2026, compared to no revenue in the prior year. Net loss reduced to $1.4 million from $4.8 million in the prior year.
Cash position: As of March 31, 2026, cash and cash equivalents were $10.2 million, with $2.2 million in receivables expected by June 2026. Resources are sufficient to fund operations through June 2027.
Melanocortin receptor platform strategy: Leveraging the platform for strategic partnerships and business development to generate nondilutive capital and support pipeline advancements.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Dependency on Partnerships: The company's revenue is heavily reliant on collaboration and licensing agreements, as evidenced by the significant revenue increase from the Altanispac agreement. This dependency poses a risk if future partnerships or milestone payments do not materialize as expected.
Operating Expenses: Operating expenses have increased due to higher compensation costs and professional fees, which could strain financial resources if revenue growth does not keep pace.
Cash Flow and Liquidity: While the company has sufficient cash to fund operations through June 2027, any delays in receivables or unexpected expenses could impact liquidity and operational continuity.
Regulatory and Development Risks: The company's lead clinical asset, a once-weekly melanocortin-4 receptor selective peptide agonist, is on track for an IND submission in late 2026. Any delays or failures in regulatory approval processes could significantly impact strategic objectives.
Market Competition: The company is focused on developing best-in-class therapies for rare obesity disorders. However, competitive pressures in the pharmaceutical industry could challenge market share and profitability.
Therapeutic Limitations: Current therapies for rare obesity disorders face challenges such as hyperpigmentation and long-term usability. The company's ability to address these limitations will be critical for patient adoption and sustained outcomes.
Strategic Execution: The company is pursuing multiple programs and partnerships simultaneously. Effective execution of these initiatives is crucial, and any mismanagement could dilute focus and resources.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Advancement of melanocortin-4 receptor agonist therapies: Palatin is focused on developing best-in-class melanocortin-4 receptor agonist therapies for rare syndromic and genetic obesity disorders. The company aims to improve tolerability, usability, and long-term outcomes in chronic treatment settings.
Pipeline updates: The once-weekly melanocortin-4 receptor selective peptide agonist is on track for an initial new drug application (NDA) submission in Q4 2026. The oral small molecule program is advancing next-generation candidates for an IND submission in H1 2027.
Strategic partnerships: Palatin continues to leverage its melanocortin receptor platform through partnerships, including collaborations with Boehringer Ingelheim for retinal diseases and sublicensing agreements for PL-9643 and PL-8177.
NDA submission timeline: The once-weekly melanocortin-4 receptor selective peptide agonist is expected to have an NDA submission in Q4 2026.
IND submission timeline: Next-generation oral melanocortin-4 receptor selective agonist candidates are targeted for an IND submission in H1 2027.
Improved therapy profiles: Palatin aims to develop therapies with superior efficacy, improved selectivity, and better long-term patient compliance, addressing limitations such as hyperpigmentation associated with current treatments.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Is the molecule PL7737 now discontinued, and if so, was it due to an issue with PL7737 or better backup compounds?
A:PL7737 is not being pursued further due to its inability to meet the stringent selectivity and dosing criteria required to be best-in-class. Additionally, backup compounds with better profiles, including near elimination of MCR1 activity, have emerged. The decision was multifactorial, considering competition and the need for highly selective, patient-friendly compounds.
Q:Will the next-generation oral small molecule compound follow a similar clinical game plan as PL-7737?
A:Yes, the next-generation oral small molecule compound will follow a similar clinical path, targeting hypothalamic obesity and Prader-Willi syndrome. The compounds are expected to have no MCR1 activity, making them cleaner and more advanced.
Q:What are the key attributes that differentiate your pipeline from competitors?
A:Key attributes include selectivity, reduced hyperpigmentation, once-a-week injection technology for peptides, better drug-like characteristics, and limited brain penetration for small molecules. These advancements aim to improve patient usability, efficacy, and side effect profiles.
Q:How does your pipeline compare to Rhythm's products, and how far behind are you?
A:Rhythm's setmelanotide is a first-generation peptide with limitations like MCR1 activity and daily injections. The company believes its compounds will be cleaner, with better drug-like characteristics and PK parameters. While Rhythm is several years ahead in approved indications, the company estimates being 1-1.5 years behind in pipeline development, focusing on delivering better patient compliance and usability.
Q:What challenges do you foresee in making the new oral compound IND-ready next year?
A:The company is confident in its understanding of the pharmacophores and drugability of the compounds. However, until preclinical studies are completed, including animal testing, the outcome remains uncertain. The process involves evaluating efficacy, selectivity, side effect profiles, and metabolism.
Q:Is the new oral compound already in animal studies?
A:Some candidates are in animal studies, while others are further back in development. A final selection for the candidate to move forward will be made later in the year.
Q:Why has the subcutaneous weekly peptide program been slightly delayed?
A:The delay is due to ensuring the selection of the best candidate, leveraging advancements in understanding receptor-ligand interactions and eliminating MCR1 activity. The program is progressing well and entering IND-enabling studies.
Q:Will Prader-Willi syndrome (PWC) be prioritized over hypothalamic obesity (HO)?
A:Both PWC and HO are considered equal priorities due to their high medical need and commercial potential. The decision to prioritize will depend on available resources.
Q:Is the goal of the new oral compound to eliminate hyperpigmentation entirely or reduce its frequency and severity?
A:The goal is to eliminate hyperpigmentation activity entirely, though some small amount may appear during chronic treatment. Preclinical studies show significant separation between MCR1 and MCR4 activity.
Q:What preclinical species or models are most predictive for MC1R-mediated hyperpigmentation?
A:Animal models like rats, dogs, and mice are used, focusing on fur darkening rather than skin pigmentation. These models are considered predictive for human conditions.
Q:What are the key IND-enabling studies remaining for the once-weekly injectable?
A:The IND-enabling studies include in vitro assays for SIP binding and metabolism, as well as animal studies. These are required to compile documentation for FDA submission in Q4.
Q:Review of Unclear Management Responses
A:Management avoided providing a clear timeline for how far behind they are compared to Rhythm's pipeline, stating uncertainty about the exact gap (1-1.5 years) and emphasizing the focus on delivering better compounds. Additionally, they did not provide specific details on the challenges or outcomes of the IND-enabling studies for the oral compound and weekly injectable, citing the unpredictability of preclinical results.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO Director
Co Founder
Director Today
Dr Spana
Founder President
Officer today
President CEO
Secretary hello
ability timing
addition receivables
agreement period
cash collaboration
cash resource
collaboration license
commitment increase
consideration agreement
development plan
equivalent addition
fee cash
hello result
improvement loss
increase compensation
increase recognition
license balance
license loss
license period
liquidity position
loss collaboration
loss share
period gain
period improvement
period reduction
plan ability
priority Palatin
receivables Co
receivables development
recognition consideration
reduction cash
release Palatin
resource receivables
result collaboration
PTN Transcript
Palatin Technologies, Inc. (PTN) Q3 2026 Earnings Call Transcript
Positive5-13
The earnings call highlights significant progress in product development, with promising next-generation compounds and a strong focus on differentiation, which is positively viewed by analysts. The financial performance shows reduced losses and a strong cash position, supporting future growth. The Q&A reveals confidence in the pipeline's potential and strategic prioritization. Despite some uncertainties in timelines and preclinical outcomes, the overall sentiment is positive, suggesting a likely stock price increase of 2% to 8% over the next two weeks.
Conagra Brands, Inc. (CAG) Presents at Consumer Analyst Group of New York Conference 2026 Prepared Remarks Transcript
Neutral2-17
Palatin Technologies, Inc. (PTN) Q2 2026 Earnings Call Transcript
Unknown2-17
The earnings call reveals mixed signals: while there are promising developments in obesity treatments and a significant cash increase from a public offering, the financial results show widening losses and lower other income. The Q&A highlights cautious optimism in drug development but lacks concrete timelines or efficacy data, which may concern investors. The absence of new partnerships or strong guidance further tempers enthusiasm. Given these factors, the stock is likely to remain stable in the short term, leading to a neutral prediction.
Palatin Technologies, Inc. (PTN) Q1 2026 Earnings Call Transcript
Positive11-13
The earnings call highlights strong financial performance with increased revenue and net income due to the BI agreement. Operating expenses decreased, improving cash flow. The Q&A revealed confidence in product differentiation and market potential despite competitive risks. The BI milestone payment and recent public offering enhance financial health. Overall, the financial and strategic outlook is positive, with potential for further growth from pipeline developments.
PTN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
